Revance Therapeutics, Inc.
$ 3.65
0.00%
07 Aug - close price
- Market Cap 381,024,000 USD
- Current Price $ 3.65
- High / Low $ 3.65 / 3.65
- Stock P/E N/A
- Book Value -1.55
- EPS -3.34
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -20.97 %
- 52 Week High 0.00
- 52 Week Low 0.00
About
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Analyst Target Price
$9.47
Quarterly Earnings
| Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-28 | 2022-11-08 | 2022-08-09 | 2022-05-10 | 2022-02-28 |
| Reported EPS | -0.37 | -0.36 | -0.58 | -0.62 | -1.63 | -0.8 | -0.74 | -0.95 | -1.17 | -0.88 | -0.94 | -0.93 |
| Estimated EPS | -0.38 | -0.53 | -0.75 | -0.72 | -0.85 | -0.78 | -0.7 | -0.95 | -0.89 | -0.86 | -0.83 | -1 |
| Surprise | 0.01 | 0.17 | 0.17 | 0.1 | -0.78 | -0.02 | -0.04 | 0 | -0.28 | -0.02 | -0.11 | 0.07 |
| Surprise Percentage | 2.6316% | 32.0755% | 22.6667% | 13.8889% | -91.7647% | -2.5641% | -5.7143% | 0% | -31.4607% | -2.3256% | -13.253% | 7% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVNC
2026-07-18 16:10:39
This article provides a key metrics overview for the RVNC5133129 bond issued by Revance Therapeutics, Inc. The bond has a coupon of 1.75%, an issue date of February 16, 2021, and matures on February 15, 2027, with an outstanding amount of $155,000 USD. Revance Therapeutics is a clinical-stage biotechnology company focused on developing botulinum toxin products for aesthetic and therapeutic applications.
2026-06-23 13:00:41
Revance has partnered with Julianne Hough as the new celebrity brand ambassador for DAXXIFY, an injectable treatment for frown lines. This collaboration aims to increase consumer awareness and education about DAXXIFY's fast-acting and long-lasting peptide formulation. Hough will be featured in a social media campaign, sharing her personal experience and advocating for the product.
2026-06-23 12:41:34
Revance has announced Julianne Hough as the celebrity brand partner for DAXXIFY (daxibotulinumtoxinA-lanm for injection), their innovative frown line treatment. Hough, a dancer, actress, and host, shared that DAXXIFY fits her busy lifestyle due to its fast-acting and long-lasting effects. The partnership aims to increase consumer awareness and education about DAXXIFY through a social media campaign featuring Hough.
2026-06-08 21:41:00
Revance Therapeutics, Inc. (RVNC) currently trades at $3.65, with analysts holding a consensus "Hold" rating based on 22 analysts, including 10 buys, 12 holds, and 0 sells. The 12-month average price target is $20.78, representing a significant potential upside of +469.3% from the current price. Recent analyst actions include several downgrades from firms like Barclays, Needham, and Guggenheim.
2026-06-02 10:41:10
Faruqi & Faruqi, LLP is investigating potential claims against Revance Therapeutics, Inc. (NASDAQ: RVNC) and reminds investors of the February 8, 2022, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Revance Therapeutics made false or misleading statements regarding quality control deficiencies at its manufacturing facility, which impacted the FDA approval process for its DAXI product. Investors who suffered losses exceeding $100,000 between November 25, 2019, and October 11, 2021, are encouraged to contact the firm.
2026-05-11 16:20:00
Investors who bought Revance Therapeutics Inc. securities (common stock or 1.75% fixed coupon convertible senior unsecured notes) between February 29, 2024, and February 6, 2025, may be eligible for a cash payment from a $17 million class action settlement. The lawsuit alleged that Revance and its executives made misleading statements and omitted material facts regarding the company's relationship with Teoxane SA and the merger with Crown Laboratories Inc., artificially inflating security prices. The deadline to file a claim is August 28, 2026.
